@article {8299,
	title = {Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.},
	journal = {Expert Rev Clin Immunol},
	volume = {12},
	year = {2016},
	month = {2016 Jun},
	pages = {641-9},
	abstract = {<p>Juvenile Idiopathic Arthritis (JIA) encompasses a group of diseases of unknown etiology having in common arthritis in at least 1 joint that persists for 6 weeks and begins before 16 years of age, with other conditions excluded. With a prevalence of 1 per 1,000 children in the USA, JIA is the most common pediatric rheumatic illness and a major cause of acquired childhood disability. During the last 20 years, the advent of host immune response modifiers known as biologic agents, in particular the anti-TNFα agents (etanercept, infliximab, adalimumab), which directly inhibit the action of pro-inflammatory mediators, has revolutionized the treatment and the expected outcome of JIA. This article highlights treatment indications of anti-TNFα drugs and their more frequent side effects in JIA patients.</p>},
	issn = {1744-8409},
	doi = {10.1586/1744666X.2016.1146132},
	author = {Taddio, Andrea and Cattalini, Marco and Simonini, Gabriele and Cimaz, Rolando}
}
